The 2026 BIO International Convention reinforced a message that has been building throughout the year: While life sciences companies continue to navigate significant regulatory, geopolitical and financing uncertainty, the market is showing increasing signs of constructive activity. Strategic transactions are accelerating, capital markets are reopening selectively, and companies are adapting to a landscape where flexibility and execution matter more than ever.

Across discussions on M&A, financing, partnering and policy developments, several themes emerged that will influence how companies are built, financed and positioned for strategic opportunities.

Optionality has become a strategic imperative

One of the strongest themes from BIO 2026 was the importance of maintaining strategic optionality. Companies can no longer assume that a single path – whether an IPO, acquisition or financing – will remain available throughout their life cycle. Instead, management teams increasingly are pursuing multiple parallel strategies, preserving flexibility as conditions evolve.

In the current environment, optionality is increasingly viewed as a competitive advantage. Companies that preserve multiple paths forward can respond more effectively to shifts in capital markets, changes in strategic buyer interest and broader industry developments.

The market is improving, but selectivity remains high

Sentiment across BIO was notably more constructive than in recent years. M&A activity has accelerated, IPO activity has started to recover, and follow-on financing markets have strengthened. Pharmaceutical companies remain active buyers, driven in part by looming loss-of-exclusivity challenges and ongoing demand for innovative assets. At the same time, investors consistently emphasized that this is not a return to the market conditions of 2020 and 2021.

Capital remains highly selective. Investors increasingly prioritize clinical validation, experienced leadership teams and clearly defined value-inflection milestones. Companies seeking financing are expected to demonstrate not only a compelling vision, but also a realistic and disciplined plan for creating value. The result is a market that is open but demanding.

Capital efficiency continues to separate winners from the field

Across multiple investor discussions, capital efficiency emerged as a defining characteristic of successful companies. Investors continue to scrutinize how management teams allocate resources and whether development plans are appropriately focused on meaningful inflection points. The emphasis has shifted away from broad platform expansion toward disciplined execution and efficient value creation.

Companies that can reach important clinical or regulatory milestones using less capital are increasingly viewed as more attractive investment opportunities. Management teams are therefore being forced to make difficult prioritization decisions earlier than in previous cycles. The ability to concentrate resources around high-conviction opportunities is becoming a significant competitive differentiator.

Regulatory and geopolitical considerations are becoming structural business issues

Policy developments are increasingly influencing strategic planning in life sciences. The BIO discussions surrounding most-favored-nation (MFN) pricing proposals highlighted how regulatory developments are now affecting transaction structures, partnership negotiations and long-term commercialization planning. What once may have been viewed primarily as government affairs concerns are becoming drivers of deal structures.

At the same time, broader geopolitical issues, including national security considerations, supply chain resilience and international pricing pressure, continue to influence decision-making across the sector. Executives can no longer treat policy developments as external risks that can be monitored from a distance. Companies that integrate regulatory and geopolitical awareness into business development, financing and strategic planning efforts are better positioned to respond to a rapidly evolving environment.

Leadership and execution matter more than ever

A recurring theme throughout the day was that strong science alone is no longer sufficient. Successful management teams increasingly are distinguished by their ability to communicate clearly, align stakeholders and make difficult strategic decisions under uncertain conditions.

Looking ahead

BIO 2026 reflected an industry that is adapting rather than retreating. While regulatory uncertainty, geopolitical complexity and capital constraints remain important challenges, companies continue to find opportunities to create value through disciplined execution, strategic partnerships and thoughtful transaction planning.

The companies best positioned to succeed are not necessarily those pursuing the boldest strategy. Rather, they are the organizations that combine scientific differentiation with strategic flexibility, operational rigor and a clear understanding of the multiple paths available to create long-term value.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.